Lymphoma News and Research

RSS
Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
Mutations may underlie how the most aggressive lymphomas arise and resist therapies

Mutations may underlie how the most aggressive lymphomas arise and resist therapies

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

The diverse mechanisms by which galectins can regulate adaptive and innate immune responses

The diverse mechanisms by which galectins can regulate adaptive and innate immune responses

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two major hallmarks of quality

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two major hallmarks of quality

Protein discovery could lead to more effective treatments for lymphoma and lung cancer

Protein discovery could lead to more effective treatments for lymphoma and lung cancer

Comprehensive atlas of protein kinases could help scientists decipher many cellular signaling pathways

Comprehensive atlas of protein kinases could help scientists decipher many cellular signaling pathways

Simple method increases the efficacy of T cell therapy by cytokine conjugation

Simple method increases the efficacy of T cell therapy by cytokine conjugation

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

Analyzing electronic medical records to identify COVID-19 sequelae

Analyzing electronic medical records to identify COVID-19 sequelae

Study suggests a strategy for preventing the progression of chronic leukemia to aggressive disease

Study suggests a strategy for preventing the progression of chronic leukemia to aggressive disease

Researchers discover a protein linked with the onset of anthracycline-associated cardiac toxicity

Researchers discover a protein linked with the onset of anthracycline-associated cardiac toxicity

COVID-19 vaccination protects people with B cell lymphoma and multiple myeloma

COVID-19 vaccination protects people with B cell lymphoma and multiple myeloma

Impact of epigenetics on the clinical management of cancer patients

Impact of epigenetics on the clinical management of cancer patients

‘Caged … for no fault of your own’: Detainees dread covid while awaiting immigration hearings

‘Caged … for no fault of your own’: Detainees dread covid while awaiting immigration hearings

BGI cares - 2022 social responsibilities in review

BGI cares - 2022 social responsibilities in review

Inhibiting inflammatory signaling pathway could reduce the chances of heart disease in cancer survivors

Inhibiting inflammatory signaling pathway could reduce the chances of heart disease in cancer survivors

Study: Only 30% of people with neuroendocrine tumors consider living longer as top priority

Study: Only 30% of people with neuroendocrine tumors consider living longer as top priority

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma

Anaplastic large-cell lymphoma risk after reconstructive surgery is extremely low, study finds

Anaplastic large-cell lymphoma risk after reconstructive surgery is extremely low, study finds

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.